Phase 3 Readout~month

Phase 3 Topline: ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With

Indication
Prostatic Neoplasms

Other upcoming events for SPRY

Phase 3 ReadoutPhase 3 Topline: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abirat
Patent ExpiryPatent/Exclusivity Expiry: FIRMAGON

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With — SPRY Phase 3 Readout | BioSniper